Company profile: Sanifit
1.1 - Company Overview
Company description
- Provider of biotechnology therapies for calcification disorders, developing SNF472 in phase 3 for calciphylaxis associated with chronic kidney disease and dialysis, and for peripheral artery disease in end-stage kidney disease, aiming to reduce arterial and cardiovascular calcification; supported by the CaLIPSO phase 2b trial showing significant reduction in coronary artery calcium progression in dialysis patients.
Products and services
- CaLIPSO study: Phase 2b–validated clinical assessment that quantified SNF472’s ability to slow arterial calcification in dialysis patients, demonstrating significant reduction in coronary artery calcium progression
- SNF472 for calciphylaxis: Phase 3 investigational therapy engineered to block cardiovascular calcification progression in a rare disease linked to chronic kidney disease and dialysis
- SNF472 for peripheral artery disease in end-stage kidney disease: Phase 3 clinical-stage agent created to reduce arterial calcification in ESKD patients with PAD
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sanifit
Vesper Medical
HQ: United States
Website
- Description: Provider of venous stenting solutions for deep venous disease, centered on the purpose-built Vesper DUO Venous Stent System, a portfolio of self-expanding nitinol stents to improve luminal diameter in symptomatic venous outflow obstructions, including DUO-HYBRID and DUO-EXTEND, and the VIVID clinical trial evaluating safety and efficacy in iliofemoral occlusive disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vesper Medical company profile →
Tarilian Laser Technologies
HQ: United Kingdom
Website
- Description: Provider of medical technology pioneering an innovative breakthrough in blood pressure monitoring through an unobtrusive wrist-worn wearable device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tarilian Laser Technologies company profile →
Renovacor
HQ: United States
Website
- Description: Provider of preclinical-stage biopharmaceutical development of transformative gene therapy-based treatments for cardiovascular disease, featuring a lead recombinant adeno-associated virus (AAV) gene therapy program for patients with dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renovacor company profile →
Action Pharma
HQ: Denmark
Website
- Description: Provider of R&D-focused drug discovery and development, creating pharmaceutical products and treatment concepts for cardiovascular and inflammatory diseases and acquired metabolic diseases, including type-II diabetes and obesity; product pipeline includes AP214.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Action Pharma company profile →
VNUS
HQ: United States
Website
- Description: Provider of products and minimally invasive treatments for venous diseases, including the patented Closure System for patients with symptoms associated with venous reflux; a world leader in the development and marketing of minimally invasive treatments for venous diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VNUS company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sanifit
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sanifit
2.2 - Growth funds investing in similar companies to Sanifit
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sanifit
4.2 - Public trading comparable groups for Sanifit
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →